The risk of a serious blood clot from AstraZeneca jab has doubled in a fortnight, new data show. Cases have gone up from 79 to 168 and deaths from 19 to 32. The chance of having a clot following vaccination has gone from one in 250,000 to one in 126,582.
Australian Federal health authorities are investigating the death of a 48-year-old New South Wales woman who developed blood clots after receiving a COVID-19 vaccine. If it is confirmed the woman contracted blood clots linked to a COVID-19 vaccine, it would be the third such case in Australia since the rollout began.
Europe’s drugs regulator is reviewing possible links between blood clots and Johnson & Johnson’s coronavirus vaccine. It comes after four serious cases of rare clots with low platelets were reported after the COVID-19 jab, one of which was fatal, according to the European Medicines Agency (EMA).
The Johnson & Johnson (also known as Janssen) vaccine, which has proved 67% effective in preventing coronavirus and completely effective at preventing hospital admissions and death from the virus during trials, is currently only used in the USA, under an emergency use authorisation.
Australia’s medical authorities are monitoring the first reported case of a rare clotting disorder following a COVID-19 jab.
A 44-year-old man was admitted to Box Hill Hospital in Melbourne’s eastern suburbs on Friday for blood clots. The man was vaccinated around March 22 and, so far, no direct link has been discovered between his condition and his vaccination. To date more than 420,000 people have received AstraZeneca vaccinations in Australia.
The Norwegian Institute of Public Health has paused vaccination with COVID-19 Vaccine AstraZeneca after we became aware of cases of serious suspected side effects with the combination of blood clots, bleeding and low platelet counts. As of March 23, five such cases have been reported, three of the reports concern deaths, the other two are being treated in hospital. The Norwegian Medicines Agency believes that there is a probable connection with the AstraZeneca vaccine and these rare cases.
Further research is needed to clarify what triggers the rare disease picture. NIPH will decide on the further use of the AstraZeneca vaccine and will provide an update at the end of week 12.
Adverse reaction reports we have received do not provide a basis for changing the current recommendations for vaccination with Comirnaty (BioNtech / Pfizer) and COVID-19 vaccine Moderna.
Another Swedish case is now being investigated for a suspected connection between blood clots and AstraZeneca’s vaccine. It concerns a woman employed in care in the 30s, who now receives intensive care, the Medical Products Agency states.
This is the second confirmed case in Sweden where it concerns an established combination of blood clots and low levels of platelets in a person who has received AstraZeneca’s corona vaccine.
Scientists at Greifswald teaching hospital claim they have discovered the cause of blood clots among a small number of AstraZeneca vaccine recipients. Doctors say a targeted treatment can now be used.
Researchers at the Greifswald teaching hospital in northern Germany said on Friday that they had discovered the cause of the unusual blood clotting found in some recipients of the AstraZeneca coronavirus vaccine, public broadcaster Norddeutscher Rundfunk (NDR) reported.
The investigation showed how the vaccine caused rare thrombosis in the brain in a small number of patients. The discovery means that targeted treatment can be offered to those who suffer similar clotting, using a very common medication.
The researchers emphasized that treatment would only be possible in patients where blood clots appear, rather than as a preventative treatment.
Another health worker in Norway has died of a brain haemorrhage after receiving the AstraZeneca anti-Covid vaccine, though no direct link to the jab has been established, health authorities said Monday. This is the second such fatality within a few days in the Nordic country, which had suspended the use of the AstraZeneca vaccine as a precaution last Thursday.